Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.
Sarcoidosis vasculitis and diffuse lung diseases · 13.09.2023 · 40 (3) · e2023029-e2023029
DOI: 10.36141/svdld.v40i3.14418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 13.09.2023. Verfasst von Sibel Günay und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Diseases, Ankara Bilkent City Hospital, Ankara, Turkiye . sibelgunay@gmail.com. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: We aimed to evaluate the pulmonary involvement status, its related factors, and pulmonary function test (PFT) results in the first month follow-up in patients who were discharged for severe Covid-19 pneumonia, and to assess the efficacy of corticosteroid treatment on these parameters in severe pulmonary involvement patients. METHODS: We retrospectively analyzed all consecutive patients who applied to our COVID-19 follow-up clinic at the end of the first month of hospital discharge. Functional and radiological differences were compared after 3 months of corticosteroid treatment in severe pulmonary involvement group. Results We analyzed 391 patients with "pulmonary parenchymal involvement" (PPIG) and 162 patients with "normal lung radiology" (NLRG). 122 patients in the PPIG (corticosteroid-required interstitial lung disease group (CRILD)) had severe pulmonary involvement with frequent symptoms and required corticosteroid prescription. Pulmonary involvement was more common in males and elder patients (P
Schlagwörter
Autor:innen und Institutionen
- Department of Pulmonary Diseases, Ankara Bilkent City Hospital, Ankara, Turkiye . sibelgunay@gmail.com.
- Department of Radiology, Ankara Bilkent City Hospital, Ankara, Turkiye . selcukparlakdr@gmail.com.
- Department of Pulmonary Diseases, Ankara Bilkent City Hospital, Ankara, Turkiye . hoflaz@yahoo.com.
- . ebrusengulparlak@gmail.com.
- Department of Pulmonary Diseases, Ankara Bilkent City Hospital, Ankara, Turkiye . melikeerdas@gmail.com.
- Department of Pulmonary Diseases, Ankara Bilkent City Hospital, Ankara, Turkiye . dr.zeynepcinar@hotmail.com.
Zitieren
APA
Günay, S., Parlak, I. S., Hezer, H., Şeref Parlak, E. Ş., Umut, M. S., Hancıoğlu, Z., Çelenk Ergüden, H., Kocaman, Y., Dalkıran, A., Sertçelik, Ü., Şerifoğlu, İ., Akpınar, E., Göktaş, M. F., Fidan, M., Babahanoğlu, B., Cander, F. S., Çıvgın, E., Er, M., Kılıç, H., …, & Karalezli, A. (2023). Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up. Sarcoidosis vasculitis and diffuse lung diseases, 40(3), e2023029-e2023029. https://doi.org/10.36141/svdld.v40i3.14418
Vancouver
Günay S, Parlak IS, Hezer H, Şeref Parlak EŞ, Umut MS, Hancıoğlu Z, et al. Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up. Sarcoidosis vasculitis and diffuse lung diseases. 2023;40(3):e2023029-e2023029. doi:10.36141/svdld.v40i3.14418
BibTeX
@article{Gnay2023,
author = {Günay, Sibel and Parlak, Izzet Selcuk and Hezer, Habibe and Şeref Parlak, Ebru Şengül and Umut, Melike Sanem and Hancıoğlu, Zeynep and Çelenk Ergüden, Hülya and Kocaman, Yasin and Dalkıran, Aynil and Sertçelik, Ümran and Şerifoğlu, İrem and Akpınar, Esmehan and Göktaş, Muhammet Furkan and Fidan, Meltem and Babahanoğlu, Büşra and Cander, Fatma Sinem and Çıvgın, Esra and Er, Mükremin and Kılıç, Hatice and Argüder, Emine and Tuğ, Tuncer and Ünsal, Ebru and Hasanoğlu, Canan and Günay, İrem and Babayiğit, Muhammet and Ağca, Büşra and Karalezli, Ayşegül},
title = {Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2023},
volume = {40},
number = {3},
pages = {e2023029--e2023029},
doi = {10.36141/svdld.v40i3.14418}
}
EUVIMED